Qiagen Acquires UK's DxS in Deal Worth up to $130M | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen said today that it has acquired UK-based companion diagnostics firm DxS in a deal that could be worth as much as $130 million.

Qiagen said that the acquisition provides it with a strong leadership position in the personalized healthcare arena.

Further supporting that claim, Qiagen also disclosed that it has more than 15 collaborations with pharmaceutical companies to develop and/or market companion diagnostic products, which it believes is the deepest such portfolio in the industry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.